LSD1-CHD1 Interaction Inhibitor for Prostate Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for prostate cancer and other cancers involving LSD1 lack selective compounds that inhibit AR-dependent gene transcription and chromosomal rearrangements, often interfering with other signal transduction pathways.
Innovation Solution
Development of compounds that specifically inhibit the interaction between methylated LSD1 and CHD1, targeting the interface between LSD1me2 and CHD1 to block androgen-dependent gene expression and chromosomal rearrangements, such as the TMPRSS2-ERG fusion, while preserving interactions with H3K4me3.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are used to inhibit LSD1 activity in prostate cancer therapy, then androgen-dependent gene transcription is blocked, but other signal transduction pathways are interfered with due to lack of selectivity
Solution Approach 1:
The compound is designed to specifically target the methylated LSD1-CHD1 interaction interface rather than inhibiting LSD1's general demethylase activity. By focusing on the unique structural features of the methylated LSD1-CHD1 complex, the compound achieves selective inhibition of AR-dependent transcription while preserving other signal transduction pathways that depend on LSD1's broader enzymatic functions.
Solution Approach 2:
The compound acts as an intermediary molecule that specifically binds to the interface between methylated LSD1 and CHD1, blocking their interaction without affecting LSD1's catalytic activity toward histones. This intermediary approach allows selective disruption of the pathological LSD1-CHD1 complex while leaving other LSD1-mediated processes intact.
2Adaptability or versatility
If broad-spectrum LSD1 inhibitors are used to treat cancer, then multiple cancer types may be addressed, but selectivity is reduced leading to interference with normal cellular functions
Solution Approach 1:
The compound targets a specific local feature (methylated LSD1-CHD1 interaction interface) that is overexpressed or aberrantly activated in multiple cancer types including prostate cancer, breast cancer, and leukemia. This localized targeting approach enables broad cancer type applicability while maintaining high selectivity for the pathological interaction, avoiding interference with normal cellular functions.
3Object-affected harmful factors
If compounds targeting methylated LSD1-CHD1 interaction are developed, then selective inhibition of AR-dependent gene transcription is achieved, but complexity of identifying and optimizing such compounds increases
Solution Approach 1:
The patent extracts and isolates the specific interaction interface between methylated LSD1 and CHD1 as the target for compound development. By focusing on this discrete molecular interface rather than the entire LSD1 protein, the screening and optimization process is simplified while maintaining high selectivity. The compound is designed to fit specifically into this extracted interaction interface, blocking it without affecting other LSD1 functions.
Data Source
AI summary
Disclosed in the present application are: (i) a compound inhibiting the interaction between LSD1me2 and CHD1 for use in therapy, (ii) a compound inhibiting the interaction between LSD1me2 and CHD1 for use in treating cancer, in particular prostate cancer, and (iii) a method of screening for such a compound.